Events Calendar

Mon
Tue
Wed
Thu
Fri
Sat
Sun
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
11
12
13
14
15
16
17
18
19
20
22
23
25
26
27
28
29
30
31
1
2
3
Electronic Medical Records Boot Camp
2025-06-30 - 2025-07-01    
10:30 am - 5:30 pm
The Electronic Medical Records Boot Camp is a two-day intensive boot camp of seminars and hands-on analytical sessions to provide an overview of electronic health [...]
AI in Healthcare Forum
2025-07-10 - 2025-07-11    
10:00 am - 5:00 pm
Jeff Thomas, Senior Vice President and Chief Technology Officer, shares how the migration not only saved the organization millions of dollars but also led to [...]
28th World Congress on  Nursing, Pharmacology and Healthcare
2025-07-21 - 2025-07-22    
10:00 am - 5:00 pm
To Collaborate Scientific Professionals around the World Conference Date:  July 21-22, 2025
5th World Congress on  Cardiovascular Medicine Pharmacology
2025-07-24 - 2025-07-25    
10:00 am - 5:00 pm
About Conference The 5th World Congress on Cardiovascular Medicine Pharmacology, scheduled for July 24-25, 2025 in Paris, France, invites experts, researchers, and clinicians to explore [...]
Events on 2025-06-30
Events on 2025-07-10
AI in Healthcare Forum
10 Jul 25
New York
Events on 2025-07-21
Events on 2025-07-24
Latest News

OptimizeRx Announces Q4 2014 Results

OptimizeRx Announces Q4 2014 Results

Good day everyone and welcome to the OptimizeRx Corporation 2014 Annual Earnings Conference Call.

Following the initial discussion, there will be time for question from the participants in the call. Just as a reminder today’s conference is being recorded. A transcript will be available for 90 days or those interested parties who want a copy, please contact Doug Baker, in our Rochester, Michigan Headquarters.

Now for opening remarks and introductions, I would now like to turn the conference over to Doug Baker, Chief Financial Officer for OptimizeRx.

Doug Baker – Chief Financial Officer

Thanks, Victoria. I would like to start off by welcoming everybody to the conference call. And as you know, I’m going to start off by reading the Safe Harbor statement.

This conference contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933 as amended and such Section 21E of the Securities Act of 1934 amended. These forward-looking statements should not be used to make an investment decision, the words estimate, possible and seeking and similar expressions identify forward-looking statements, which speak only as for the date the statement was made.

The company undertakes no obligation to publicly update or revise any forward-looking statements whether because of new company information, future events or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified.

Further events and actual results could differ materially from those set forth and contemplated by or underlying the forward-looking statements, the risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effective government regulation, competition and other material risk.

At this point, I am now going to turn the call over to Dave Harrell, our CEO for some opening remarks.

Dave Harrell – Chairman and Chief Executive Office

Thank you, Doug, and thanks everybody. So today I wanted to just talk about we’re going highlight today four key buckets, the first key bucket is how we’re expanding pharmaceutical brands and budgets and how we not only did in the 2014 but how we’re going to move forward very aggressively in 2015. The second bucket we’re going to talk about expanding physician utilization in our current EHR Network. The third bucket we’re going to speak to is how we’re going to have expanded our promotional network in other EHRs and platforms. And then our last bucket focuses on our fourth objective which is to expand infrastructure and resources to fully support and exploit each of our three opportunities that I just listed.

So with that I wanted to make some opening comments as it relates to pumping out our success in each of these key areas and then bringing it to each of the leaders in our departments, so that they can speak to how we’re further going to ramp it up. In regards to sustaining the pharmaceutical brands and budget as you may have realized that looking at our 10-K, we were successful expanding our sales overall by 39% over 2013. We also increased promotional transactions of approximately 26% over 2013 and Doug will speak a little bit more about our financial performance that did improve.

Source